Advertisement

Topics

Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease

20:00 EDT 31 Jul 2005 | NIH

Hypertension is a condition characterized by persistent high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or may be associated with other primary diseases (secondary hypertension), and is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke, and kidney disease. Preeclampsia is a similar condition that occurs in 5-10% of all pregnancies (most common in first time pregnancies) and is characterized by high blood pressure, edema, and protein in the urine. Complications of preeclampsia include eclampsia (convulsions and coma) and intrauterine fetal demise.

Researchers at the National Institute on Aging (NIA) have developed monoclonal antibodies and antigen binding fragments that specifically bind marinobufagenin, a steroid that, in abundance, can exacerbate pathological states associated with fluid retention, including essential and salt-sensitive hypertension, preeclampsia, and uremic cardiomyopathy. Thus, marinobufagenin may be an appropriate target in the treatment of these disorders. In addition, NIA researchers developed methods of diagnosing hypertensive disorders, e.g., by detecting the binding of antibodies against marinobufagenin in a patient sample.

IC: 
NIA
NIH Ref. No.: 
E-092-2004/0
TAB No: 
TAB-1169
Advantages: 
  • Treatment methods claimed by the patent span a wide array of indications
  • Efficient methods of diagnosing hypertensive disorders
Applications: 
  • Treatment of hypertension
  • Treatment of preeclampsia
  • Methods of diagnosing hypertensive disorders
Provider Technology ID: 
1169
Updated On: 
Jun 29, 2017
Date Published: 
Monday, August 1, 2005
Provider Classifications: 
Publications: 
Patent Application: 
60/694,733
PCT/US2006/024918
11/993,309
Patent Authority: 
US
PCT
US
Patent Number: 
8,038,997
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NIA
NIA
NIA
State Research Institute of Highly Pore Bioprepara
State Research Institute of Highly Pore Bioprepara
State Research Institute of Highly Pore Bioprepara
Inventor Lab URL: 
https://www.irp.nia.nih.gov/branches/lcs/hptu.htm
https://irp.nih.gov/pi/edward-lakatta
LPM FIrst Name: 
Richard
LPM Last Name: 
Girards
LPM Address: 
BG 9609 RM 1E508 9609 MEDICAL CENTER DR
LPM City: 
Rockville
Inv Is lead: 
LPM Zip: 
20850-9702
LPM State: 
MD
LPM Phone: 
240-276-6825
LPM Suffix: 
J.D., M.B.A.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-276-5504
DTDT Classification: 
Internal Medicine
Diagnostics
Other
Therapeutics
Other
Disease Initiatives, Rare Disease
Cardiovascular Disease
Hypertension
Diagnostic
Therapeutic (biologic)
Antibody
Early-stage
DTDT Description: 
Internal Medicine
Internal Medicine - Diagnostics
Internal Medicine - Diagnostics: Other
Internal Medicine - Therapeutics
Internal Medicine - Therapeutics: Other
Disease Initiatives, Rare Disease
Cardiovascular Disease
Hypertension
Diagnostic
Therapeutic (biologic)
Antibody
Early-stage
Pat Filing Date: 
2005-06-27
2006-06-26
2007-12-20
Patent Issue Date: 
2011-10-18
Technology Term: 
Development Stage Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

The National Institute on Aging, Laboratory of Cardiovascular Science, seeks licensing partners and statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these antibodies.

E Number Only: 
E-092-2004
Inventor First Name: 
Alexei
Olga
Edward
Andrey
Alexander
Nikolai
Inventor Last Name: 
Bagrov
Fedorova
Lakatta
Simbirtsev
Kotov
Kolodkin

Original Article: Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease

NEXT ARTICLE

More From BioPortfolio on "Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease"

Quick Search
Advertisement
 

Relevant Topics

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...